科济药业-B(02171.HK):于《The Lancet》及2025年ASCO年会上呈列的舒瑞基奥仑赛注射液研究成果

格隆汇
02 Jun

格隆汇6月2日丨科济药业-B(02171.HK)发布公告,舒瑞基奥仑赛注射液(产品编号:CT041,一款靶向Claudin18.2蛋白的自体CAR-T细胞治疗候选产品)在中国开展的针对Claudin18.2阳性、至少二线治疗失败的晚期胃╱食管胃结合部腺癌患者的确证性II期临床试验(CT041-ST-01, NCT04581473)的研究结果于2025年5月31日(英国时间)已全文发表在《The Lancet》,并于2025年5月31日(美国中部夏令时间)在2025年美国临床肿瘤学会(ASCO)年会上进行口头报告(口头报告专场-胃肠系统肿瘤)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10